BiPER TX is a biotech start-up developing first-in-class drug candidates against cancers with high unmet medical needs. Our first drug candidate, BPR001 is at 15 months from the clinic and has been developed to treat gastro-intestinal cancers in oral administration. Our first portfolio of patented small molecules target specifically BIP a key controler of the ER Stress, a pro-survival and resistance pathway, leading to tumour growth inhibition in a broad range of cancer indications.